Internal dose assessment intercomparison exercises offer several advantages. They help verifying the performance of an internal dosimetry service, promote the harmonization of dose assessments, and identify areas for improvement. In 2017, the Internal Dosimetry Group (WG7) of EURADOS organized an intercomparison entitled ICIDOSE 2017. The primary aim of this initiative was to test the practical applicability of new technical recommendations issued by the European Commission (RP188).


Four case studies with different degrees of complexity were distributed to the participants: 


  • Simple special monitoring of Co-60
  • Simple routine monitoring of I-125
  • Complex confirmatory and special monitoring of U-234, U-235 and U-238
  • Very complex special monitoring of Am-241 after an accident 

Results were received from 66 participants from 26 countries.








A new intercomparison exercise, ICIDOSE#2, is scheduled for 2024 and will once again be organized by EURADOS WG7. The objective of ICIDOSE#2 is for participants to assess internal dose according to either the most recent recommendations (RP188, ICRP OIR Report Series) or to the standards for accreditation. The exercise consists of five different cases, varying in complexity from simple to more challenging scenarios.

  • Straightforward scenario involving Cs-137 whole-body counter measurements
  • Case study featuring data on thyroid and urine measurements for I-131
  • Tritium in urine monitoring data over a period of several months
  • Case involving wounds contaminated with Pu-239, Pu-240, Am-241
  • Particularly unique scenario focusing on the inhalation of S-35 by a pregnant worker 


Some cases feature only a limited number of (early-phase) data points, whereas others have more extensive data available over extended periods. Moreover, dose assessments will rely on prolonged monitoring intervals, such as records covering an entire year. The intercomparison covers scenarios including dose assessments after routine monitoring, subsequent assessments following negative results, as well as considerations for new intakes necessitating special monitoring. Additionally, a special case is included, specifically designed to prompt a reevaluation of established methodologies.


Participants are not obliged to respond to all cases; instead, they may select the specific case(s) for which they would like to provide responses. Each participant is permitted to submit only one solution per case, but will be able to revise their previously submitted results until the submission deadline.


ICIDOSE#2 is the first intercomparison exercise involving the dosimetry of the offspring. IDEA System provides a special tool for estimation of the committed dose to the offspring due to intakes of the mother according to ICRP Publication 88. So ICIDOSE#2 is a good opportunity for testing this tool in practice. Thus, IDEA System would like to encourage all colleagues to participate in this incomparison exercise. For this reason IDEA System offers the full versions of IDEA and IDEAplus with a 50 % discount for all participants of ICIDOSE#2. This offer is valid until the deadline for expressing interest in participating in ICIDOSE#2 (30.06.2024).

For more information please see the announcement.
Adobe Acrobat Document 681.2 KB



Prof. Dr.-Ing. Hans Richard Doerfel

IDEA System GmbH, Am Burgweg 4, D-76227 Karlsruhe, Germany.

E-Mail: info@idea-system.com